title: Changes in blood pressure following escalating doses of phenylpropanolamine and a suggested protocol for monitoring.
abstract: This prospective, cross-over, blinded study evaluated the effect of various doses of phenylpropanolamine (PPA) on blood pressure in dogs. Dogs were randomized to receive a placebo or 1 of 3 dosages of immediate release PPA, q12h for 7 days [1 mg/kg body weight (BW), 2 mg/kg BW, or 4 mg/kg BW] in a cross-over design. Blood pressure was recorded every 2 h, for 12 h, on days 1 and 7. There were significant increases in systolic, diastolic, and mean blood pressure following administration of PPA at 2 mg/kg BW and 4 mg/kg BW. A significant decrease in heart rate was also noted at all PPA dosages, but not in the placebo. Administration of PPA was associated with a dose response increase in blood pressure. Dosages of up to 2 mg/kg BW should be considered safe in healthy dogs.
authors.affiliation: School of Veterinary Medicine, the Hebrew University of Jerusalem, Israel, P.O. Box 12, Rehovot, 76100, Israel (Segev, Kulik, Lavy); Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California 95616, USA (Westropp).
authors.forename: Gilad
authors.initials: G
authors.lastname: Segev
authors.affiliation: School of Veterinary Medicine, the Hebrew University of Jerusalem, Israel, P.O. Box 12, Rehovot, 76100, Israel (Segev, Kulik, Lavy); Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California 95616, USA (Westropp).
authors.forename: Jodi L
authors.initials: JL
authors.lastname: Westropp
authors.affiliation: School of Veterinary Medicine, the Hebrew University of Jerusalem, Israel, P.O. Box 12, Rehovot, 76100, Israel (Segev, Kulik, Lavy); Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California 95616, USA (Westropp).
authors.forename: Chen
authors.initials: C
authors.lastname: Kulik
authors.affiliation: School of Veterinary Medicine, the Hebrew University of Jerusalem, Israel, P.O. Box 12, Rehovot, 76100, Israel (Segev, Kulik, Lavy); Department of Veterinary Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California 95616, USA (Westropp).
authors.forename: Eran
authors.initials: E
authors.lastname: Lavy
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D018660:Blood Pressure Monitoring, Ambulatory / Q000662:veterinary*; D018592:Cross-Over Studies; D004285:Dogs / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000316:Adrenergic alpha-Agonists; D010665:Phenylpropanolamine